Skip Nav Destination
1-1 of 1
Journal: Clinical Science
Clin Sci (Lond) (2002) 103 (s2002): 442S–445S.
Published: 01 September 2002
... refractory prostate cancer who have undergone aggressive hormone ablation therapy. It is not known how hormone ablation affects ET-binding sites, although ET-1 and ET A expression are found to be elevated in prostate cancer patients. In this study, we examined the effect of castration on ET receptor binding...